SBH
HZNP

Segall Bryant & Hamill’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Segall Bryant & Hamill’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,798
Closed -$391K – 725
2023
Q2 		$391K Hold
3,798
– – ﹤0.01% 599
2023
Q1 		$414K Sell
3,798
-126,746
-97% -$14M ﹤0.01% 597
2022
Q4 		$14.9M Sell
130,544
-51,149
-28% -$4.25M 0.17% 170
2022
Q3 		$11.2M Buy
181,693
+44,072
+32% +$3.08M 0.13% 187
2022
Q2 		$11M Sell
137,621
-25,094
-15% -$2.38M 0.12% 185
2022
Q1 		$17.1M Buy
162,715
+30,834
+23% +$3M 0.16% 152
2021
Q4 		$14.2M Sell
131,881
-4,024
-3% -$439K 0.13% 175
2021
Q3 		$14.9M Sell
135,905
-15,811
-10% -$1.64M 0.14% 164
2021
Q2 		$14.2M Buy
151,716
+15,165
+11% +$1.4M 0.14% 172
2021
Q1 		$12.6M Sell
136,551
-32,763
-19% -$2.76M 0.12% 189
2020
Q4 		$12.4M Buy
169,314
+9,136
+6% +$679K 0.14% 169
2020
Q3 		$12.4M Buy
160,178
+37,432
+30% +$2.58M 0.17% 138
2020
Q2 		$6.82M Sell
122,746
-20,904
-15% -$894K 0.11% 182
2020
Q1 		$4.26M Buy
143,650
+13,296
+10% +$450K 0.09% 217
2019
Q4 		$4.72M Sell
130,354
-6,347
-5% -$195K 0.07% 259
2019
Q3 		$3.72M Sell
136,701
-22,169
-14% -$573K 0.06% 315
2019
Q2 		$3.82M Buy
158,870
+7,389
+5% +$187K 0.06% 313
2019
Q1 		$4M Sell
151,481
-138,972
-48% -$3.29M 0.06% 305
2018
Q4 		$5.67M Sell
290,453
-173,995
-37% -$3.41M 0.1% 244
2018
Q3 		$9.09M Sell
464,448
-167,885
-27% -$3.19M 0.13% 205
2018
Q2 		$10.5M Sell
632,333
-50,777
-7% -$774K 0.16% 176
2018
Q1 		$9.7M Sell
683,110
-41,892
-6% -$619K 0.22% 114
2017
Q4 		$10.6M Buy
725,002
+81,074
+13% +$1.14M 0.23% 114
2017
Q3 		$8.16M Buy
643,928
+52,454
+9% +$667K 0.19% 129
2017
Q2 		$7.02M Buy
+591,474
New +$7.36M 0.17% 138

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Segall Bryant & Hamill's HZNP Position: Q3 2023 in Review

Segall Bryant & Hamill sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 3,798 shares — an estimated $391K sold.

Segall Bryant & Hamill first reported a position in HZNP in Q2 2017 and held it in 25 quarters. The position peaked at $17.1M in Q1 2022. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

  • Segall Bryant & Hamill reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
  • Segall Bryant & Hamill sold 3,798 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $391K.
  • Segall Bryant & Hamill first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2017 and held it in 25 quarters.
  • Segall Bryant & Hamill's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $17.1M in Q1 2022.
  • 485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Segall Bryant & Hamill's 13F filing for Q3 2023, filed 9 Nov 2023.